| Similar Articles |
|---|
 |
The Motley Fool
September 2, 2011
Brian D. Pacampara |
Regeneron Pharmaceuticals Shares Jumped: What You Need to Know Shares of drugmaker Regeneron Pharmaceuticals popped 10% in intraday trading Friday after The New York Times reported that Roche's age-related macular degeneration treatment Avastin led to vision loss in several California patients.   |
The Motley Fool
January 11, 2012
Brian Orelli |
A Year's Worth of Sales in 1 Month Regeneron's Eylea hits the gates running. |
The Motley Fool
July 23, 2011 |
Regeneron Pharmaceuticals Earnings Preview Regeneron Pharmaceuticals will unveil its latest earnings on Wednesday, July 27. |
The Motley Fool
August 18, 2011
Brian Orelli |
A Poke in the Eye From the FDA FDA extends its review of Regeneron Pharmaceuticals' macular degeneration drug by three months. |
The Motley Fool
April 29, 2011
Cindy Johnson |
Regeneron Pharmaceuticals Shares Plunged: What You Need to Know Regeneron Pharmaceuticals dropped 12% in intraday trading today after an analyst at RBC Capital downgraded the stock from outperform to sector perform. |
The Motley Fool
June 16, 2011
Brian Orelli |
No Poke in the Eye Here What's the biggest sign that the Food and Drug Administration is all set to approve Regeneron Pharmaceuticals' Eylea? The briefing documents for the advisory committee contained a proposed version of the label. |
The Motley Fool
November 21, 2011
Brian Orelli |
This Biotech Has Almost Everything Going for It Fewer injections into the eye and lower cost than the other FDA-approved drug: What's not to like about Regeneron Pharmaceuticals' Eylea, which was approved on Friday? |
The Motley Fool
November 22, 2010
Travis Hoium |
Regeneron Pharmaceuticals Shares Popped: What You Need to Know Regeneron Pharmaceuticals shares jumped 16% today after the company announced results from VEGF Trap-Eye testing. |
The Motley Fool
June 20, 2011
Brian Orelli |
See Drug, Approve Drug An approval of Regeneron's macular degeneration Eylea looks likely. |
Pharmaceutical Executive
June 1, 2013
Ben Comer |
Regeneron: New York State of Mind Led by two New Yorkers with a mindset that marries novel scientific insights to the processing power of novel technologies, Regeneron's success is a revolutionary challenge to the industry status quo. |
Registered Rep.
February 22, 2007
John Churchill |
Baird and Red Granite Call Off the Dogs The feud between regional brokerage firm Robert W. Baird and three former employees who left the firm last year has apparently been settled out of court. |
The Motley Fool
November 19, 2011
Luke Timmerman |
Regeneron Wins FDA Approval for Macular-Degeneration Drug The company can begin selling Eylea, which treats the leading cause of blindness in the elderly. |
The Motley Fool
November 12, 2009
Kris Eddy |
Drug Companies Should Think Smaller Sanofi-aventis looks to break R&D into smaller chunks; their collaboration with Regeneron Pharmaceuticals is a good example of the new strategy. |
The Motley Fool
November 23, 2010
Brian Orelli |
Less of a Poke in the Eye Regeneron Pharmaceuticals was up nearly 20% yesterday after the drugmaker announced the results for two phase 3 trials testing VEGF Trap-Eye in wet AMD patients. |
The Motley Fool
November 11, 2009
Brian Orelli |
Now That's What I Call a Drug Deal Investors are regenerating their interest in Regeneron Pharmaceuticals after it extended its drug-discovery pact with sanofi-aventis. |
The Motley Fool
November 21, 2011
David Williamson |
Market Volatility = Biotech Opportunity Gilead buys Pharmasset, Spectrum gets a break, and Eylea's approved. |
The Motley Fool
February 29, 2008
Brian Lawler |
Regeneron's Orphan Charms the FDA Regeneron Pharmaceuticals receives marketing approval from the FDA for a treatment that targets a very rare inflammatory disease. |
The Motley Fool
July 14, 2011
Brian Orelli |
Good Data, but Lots of Competition Regeneron's sarilumab passes a phase 2b trial. |
The Motley Fool
January 10, 2012
Brian Orelli |
Linear Growth Isn't Enough Human Genome Sciences needs to accelerate growth. |
The Motley Fool
August 27, 2010
Travers & Jayson |
The Most Important Thing about Regeneron Pharmaceuticals Stop obsessing about the science. |
The Motley Fool
December 27, 2010
Brian Orelli |
Painful Clinical Hold? Not Really. Regeneron offers the benefits of a full pipeline. |
The Motley Fool
October 14, 2011
Sean Williams |
7 FDA Decisions You Can't Afford to Ignore in Q4 These stocks are bound to move as the FDA weighs in on their prospective drugs in Q4: Bristol-Myers... BioSante... Teva... Regeneron... Transcept... Incyte... Antares Pharma... |
